JP2015509770A - 注射デバイスへの取付けのための補助デバイス - Google Patents
注射デバイスへの取付けのための補助デバイス Download PDFInfo
- Publication number
- JP2015509770A JP2015509770A JP2014556065A JP2014556065A JP2015509770A JP 2015509770 A JP2015509770 A JP 2015509770A JP 2014556065 A JP2014556065 A JP 2014556065A JP 2014556065 A JP2014556065 A JP 2014556065A JP 2015509770 A JP2015509770 A JP 2015509770A
- Authority
- JP
- Japan
- Prior art keywords
- auxiliary device
- dose
- window
- injection
- injection device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007924 injection Substances 0.000 title claims abstract description 270
- 238000002347 injection Methods 0.000 title claims abstract description 270
- 230000001681 protective effect Effects 0.000 claims abstract description 79
- 230000003287 optical effect Effects 0.000 claims abstract description 45
- 238000005286 illumination Methods 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims description 15
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 83
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 64
- 101000579646 Penaeus vannamei Penaeidin-1 Proteins 0.000 description 62
- 108010011459 Exenatide Proteins 0.000 description 49
- 229960001519 exenatide Drugs 0.000 description 49
- 210000004369 blood Anatomy 0.000 description 33
- 239000008280 blood Substances 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
- 108090001061 Insulin Proteins 0.000 description 31
- 102000004877 Insulin Human genes 0.000 description 31
- 239000008103 glucose Substances 0.000 description 31
- 229940125396 insulin Drugs 0.000 description 31
- 239000003814 drug Substances 0.000 description 30
- 229940079593 drug Drugs 0.000 description 27
- 238000012544 monitoring process Methods 0.000 description 23
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- 230000006870 function Effects 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 230000033001 locomotion Effects 0.000 description 15
- 238000012015 optical character recognition Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000004891 communication Methods 0.000 description 6
- 229940127560 insulin pen Drugs 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- -1 menotropin) Substances 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108010057186 Insulin Glargine Proteins 0.000 description 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 108010015174 exendin 3 Proteins 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 229940060975 lantus Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012780 transparent material Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 108010024118 Hypothalamic Hormones Proteins 0.000 description 1
- 102000015611 Hypothalamic Hormones Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940112930 apidra Drugs 0.000 description 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 108700039926 insulin glulisine Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000005236 sound signal Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31525—Dosing
- A61M5/31528—Dosing by means of rotational movements, e.g. screw-thread mechanisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31525—Dosing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J1/00—Photometry, e.g. photographic exposure meter
- G01J1/02—Details
- G01J1/08—Arrangements of light sources specially adapted for photometry standard sources, also using luminescent or radioactive material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J1/00—Photometry, e.g. photographic exposure meter
- G01J1/42—Photometry, e.g. photographic exposure meter using electric radiation detectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
- A61M2005/3126—Specific display means related to dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3561—Range local, e.g. within room or hospital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3592—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6045—General characteristics of the apparatus with identification means having complementary physical shapes for indexing or registration purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6063—Optical identification systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6063—Optical identification systems
- A61M2205/6072—Bar codes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6063—Optical identification systems
- A61M2205/6081—Colour codes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
本体と;
注射デバイスと所定の位置関係にある、補助デバイスの本体を支持するための配置と;
使用時に注射ペンの用量窓と位置合わせする、本体の表面に位置する透明な保護窓と;
本体内で支持され、保護窓に向けられたセンサを有するセンサ配置と;
それぞれが保護窓に向けられた1つまたはそれ以上の光源を有する照明配置と;
1つまたはそれ以上の光源のうちの第1の光源と、センサへの反射が生じる用量窓上の点との間の光路上に位置する非透過性部材とを備えた補助デバイスが提供される。
前に取り込まれた背景画像による分割;
画像をビニングして、さらなる評価のために画素数を減らす;
画像を正規化して、照明の強度変動を減らす;
画像の方向変え(sheering);および/または
一定の閾値を比較することにより、画像を2値化。
ここで、一実施形態において、薬学的に活性な化合物は、最大1500Daまでの分子量を有し、および/または、ペプチド、タンパク質、多糖類、ワクチン、DNA、RNA、酵素、抗体もしくはそのフラグメント、ホルモンもしくはオリゴヌクレオチド、または上述の薬学的に活性な化合物の混合物であり、
ここで、さらなる実施形態において、薬学的に活性な化合物は、糖尿病、または糖尿病性網膜症などの糖尿病関連の合併症、深部静脈血栓塞栓症または肺血栓塞栓症などの血栓塞栓症、急性冠症候群(ACS)、狭心症、心筋梗塞、がん、黄斑変性症、炎症、枯草熱、アテローム性動脈硬化症および/または関節リウマチの処置および/または予防に有用であり、
ここで、さらなる実施形態において、薬学的に活性な化合物は、糖尿病または糖尿病性網膜症などの糖尿病に関連する合併症の処置および/または予防のための少なくとも1つのペプチドを含み、
ここで、さらなる実施形態において、薬学的に活性な化合物は、少なくとも1つのヒトインスリンもしくはヒトインスリン類似体もしくは誘導体、グルカゴン様ペプチド(GLP−1)もしくはその類似体もしくは誘導体、またはエキセンジン−3もしくはエキセンジン−4もしくはエキセンジン−3もしくはエキセンジン−4の類似体もしくは誘導体を含む。
H−(Lys)4−desPro36,desPro37エキセンジン−4(1−39)−NH2、
H−(Lys)5−desPro36,desPro37エキセンジン−4(1−39)−NH2、
desPro36エキセンジン−4(1−39)、
desPro36[Asp28]エキセンジン−4(1−39)、
desPro36[IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,IsoAsp28]エキセンジン−(1−39)、
desPro36[Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Trp(O2)25,IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14Trp(O2)25,IsoAsp28]エキセンジン−4(1−39);または
desPro36[Asp28]エキセンジン−4(1−39)、
desPro36[IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,IsoAsp28]エキセンジン−(1−39)、
desPro36[Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Trp(O2)25,IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Trp(O2)25,IsoAsp28]エキセンジン−4(1−39)、
(ここで、基−Lys6−NH2が、エキセンジン−4誘導体のC−末端に結合していてもよい);
desPro36エキセンジン−4(1−39)−Lys6−NH2(AVE0010)、
H−(Lys)6−desPro36[Asp28]エキセンジン−4(1−39)−Lys6−NH2、
desAsp28Pro36,Pro37,Pro38エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro38[Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−NH2、
desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36[Trp(O2)25,Asp28]エキセンジン−4(1−39)−Lys6−NH2、
H−desAsp28Pro36,Pro37,Pro38[Trp(O2)25]エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−NH2、
desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36[Met(O)14,Asp28]エキセンジン−4(1−39)−Lys6−NH2、
desMet(O)14,Asp28Pro36,Pro37,Pro38エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−NH2;
desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Asn−(Glu)5desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Lys6−desPro36[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−Lys6−NH2、
H−desAsp28,Pro36,Pro37,Pro38[Met(O)14,Trp(O2)25]エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−NH2、
desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(S1−39)−(Lys)6−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2;
または前述のいずれか1つのエキセンジン−4誘導体の薬学的に許容される塩もしくは溶媒和化合物
から選択される。
Claims (15)
- 用量値が標示されたスリーブを覆う用量窓を備えた、注射デバイスへの取付けのための補助デバイスであって:
本体と;
注射デバイスと所定の位置関係にある、補助デバイスの該本体を支持するための配置と;
使用時に注射ペンの用量窓と位置合わせする、該本体の表面に位置する透明な保護窓と;
該本体内で支持され、該保護窓に向けられたセンサを有するセンサ配置と;
それぞれが該保護窓に向けられた1つまたはそれ以上の光源を有する照明配置と;
1つまたはそれ以上の光源のうちの第1の光源と、センサへの反射が生じる用量窓上の点との間の光路上に位置する非透過性部材とを備える前記補助デバイス。 - 保護窓が屈折力を有する、請求項1に記載の補助デバイス。
- 材料が保護窓の周りで補助デバイスに入ることを防止するように、保護窓が本体に封止される、請求項1または2に記載の補助デバイス。
- 非透過性部材が、センサ配置に最も近い保護窓の表面に設けられる、請求項1〜3のいずれか1項に記載の補助デバイス。
- 非透過性部材がブラックアウト・スポットを備える、請求項4に記載の補助デバイス。
- 非透過性部材が、保護窓を形成する材料内に設けられる、請求項1〜3のいずれか1項に記載の補助デバイス。
- 非透過性部材が、1つまたはそれ以上の光源のうちの第1の光源と、センサ配置から最も遠い用量窓の表面上の点との間の光路上に位置し、該点が、センサ配置への反射が生じる点である、請求項1〜6のいずれか1項に記載の補助デバイス。
- 非透過性部材が、1つまたはそれ以上の光源のうちの第1の光源と、センサ配置に最も近い用量窓の表面上の点との間の光路上に位置し、該点が、センサへの反射が生じる点である、請求項1〜7のいずれか1項に記載の補助デバイス。
- 照明配置が、複数の光源を備える、請求項1〜8のいずれか1項に記載の補助デバイス。
- 複数の光源が、センサ配置の周りの異なる位置に位置する、請求項9に記載の補助デバイス。
- 複数の光源が、センサ配置の周りの異なる位置で、光がセンサ配置に入るセンサ配置の部分の略平面に位置する、請求項9または10に記載の補助デバイス。
- 複数の光源が、光がセンサ配置に入るセンサ配置の部分の平面から離れて傾斜する照明パターンを有する、請求項9〜11のいずれか1項に記載の補助デバイス。
- センサ配置から最も遠い保護窓の表面が、注射デバイスの縦軸に一致する軸を有する仮想円筒の湾曲面上に位置する、請求項1〜12のいずれか1項に記載の補助デバイス。
- 請求項1〜13のいずれか1項に記載の補助デバイスと、注射デバイスとを備えたシステム。
- センサ配置から最も遠い保護窓の表面が、注射デバイスの縦軸に一致する軸を有する仮想円筒の湾曲面上に位置していてもよく、補助デバイスが注射デバイスに設置されたときに、センサ配置から最も遠い保護窓の表面が、注射デバイスの用量窓に近接して位置する、請求項14に記載のシステム。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12155200.4 | 2012-02-13 | ||
EP12155200 | 2012-02-13 | ||
US201261604704P | 2012-02-29 | 2012-02-29 | |
US61/604,704 | 2012-02-29 | ||
PCT/EP2013/052508 WO2013120776A1 (en) | 2012-02-13 | 2013-02-08 | Supplemental device for attachment to an injection device |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015509770A true JP2015509770A (ja) | 2015-04-02 |
JP2015509770A5 JP2015509770A5 (ja) | 2016-03-17 |
JP6203198B2 JP6203198B2 (ja) | 2017-09-27 |
Family
ID=48983563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014556065A Active JP6203198B2 (ja) | 2012-02-13 | 2013-02-08 | 注射デバイスへの取付けのための補助デバイス |
Country Status (14)
Country | Link |
---|---|
US (2) | US9233210B2 (ja) |
EP (1) | EP2814544B1 (ja) |
JP (1) | JP6203198B2 (ja) |
KR (1) | KR20140124813A (ja) |
CN (1) | CN104363940B (ja) |
AU (1) | AU2013220538B2 (ja) |
BR (1) | BR112014019511A8 (ja) |
DK (1) | DK2814544T3 (ja) |
HK (1) | HK1199623A1 (ja) |
IL (1) | IL233508A0 (ja) |
MX (1) | MX350049B (ja) |
RU (1) | RU2628052C2 (ja) |
TW (1) | TWI581814B (ja) |
WO (1) | WO2013120776A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019501697A (ja) * | 2015-12-10 | 2019-01-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 薬物送達デバイスに着脱可能に取り付け可能なセンサデバイス |
JP2019520880A (ja) * | 2016-05-30 | 2019-07-25 | ノボ・ノルデイスク・エー/エス | アクセサリデバイスのための取付け特徴 |
US11395882B2 (en) | 2016-08-26 | 2022-07-26 | Sanofi-Aventis Deutschland Gmbh | Device for attachment to an injection device |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2482894B1 (en) * | 2009-09-30 | 2016-07-20 | Sanofi-Aventis Deutschland GmbH | An assembly of a drug delivery device |
EP3799907A1 (en) | 2011-03-24 | 2021-04-07 | Sanofi-Aventis Deutschland GmbH | Device and method for detecting an actuation action performable with a medical device |
US10283014B2 (en) | 2012-04-04 | 2019-05-07 | Jbcb Holdings, Llc | Smart packaging and display system |
US9767708B2 (en) | 2012-04-04 | 2017-09-19 | Genia Medical Inc. | Medicament training device and system |
EP2911717B1 (en) * | 2012-10-23 | 2019-05-22 | Insuline Medical Ltd. | Drug dispensing-tracking device, system and method |
AU2013370241B2 (en) | 2012-12-27 | 2018-02-15 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
JP6392849B2 (ja) * | 2013-04-22 | 2018-09-19 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 注射デバイスに取り付けるための補助デバイス |
CN105307711B (zh) * | 2013-04-22 | 2019-08-30 | 赛诺菲-安万特德国有限公司 | 用于附接到注射装置的补充装置 |
MX2016007232A (es) * | 2013-12-06 | 2016-09-07 | Unitract Syringe Pty Ltd | Mecanismo de accionamiento para bombas para el suministro de farmacos con indicacion del estado integrada. |
JP6666253B2 (ja) * | 2014-01-24 | 2020-03-13 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 光学式文字認識(ocr)を用いて使用者が設定した用量値を記録および表示するために注射デバイスに取り付けるための補助デバイス |
US9308306B2 (en) | 2014-02-24 | 2016-04-12 | Fresenius Medical Care Holdings, Inc. | Self calibrating blood chamber |
US10166340B2 (en) | 2014-06-10 | 2019-01-01 | Sanofi-Aventis Deutschland Gmbh | Apparatus for determining information associated with reflection characteristics of a surface |
US10071205B2 (en) * | 2014-06-10 | 2018-09-11 | Sanofi-Aventis Deutschland Gmbh | Apparatus for determining information associated with reflection characteristics of a surface |
JP6866287B2 (ja) * | 2014-08-15 | 2021-04-28 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 注射デバイスおよび注射デバイスに取り付けるように構成された補助デバイス |
EP3185935B1 (en) * | 2014-08-25 | 2021-12-15 | Novo Nordisk A/S | Accessory device with snap feature |
EP3204089B1 (en) * | 2014-10-06 | 2023-10-04 | Sanofi-Aventis Deutschland GmbH | A drug delivery device with at least one transparent region of housing |
US10146910B2 (en) * | 2014-10-21 | 2018-12-04 | Sanofi-Aventis Deutschland Gmbh | Recording dose data from drug injection devices using optical character recognition (OCR) |
US10569028B2 (en) | 2014-11-05 | 2020-02-25 | Insuline Medical Ltd. | Drug tracking device |
EP3058973A1 (en) * | 2015-02-19 | 2016-08-24 | Sanofi-Aventis Deutschland GmbH | Supplemental device for removable attachment to a medicament injection device |
US10213554B2 (en) | 2015-02-27 | 2019-02-26 | Novo Nordisk A/S | Accessory device with mounting safety feature |
EP3088026A1 (en) * | 2015-04-28 | 2016-11-02 | Sanofi-Aventis Deutschland GmbH | Data collection device for a medicament delivery device |
EP3304372B1 (en) * | 2015-05-29 | 2018-12-26 | Insulcloud, S.L. | Monitoring device for drug application with a drug pen, with logging, communication and alarms |
CN113456946B (zh) * | 2015-06-09 | 2023-12-26 | 赛诺菲-安万特德国有限公司 | 用于附接到注射装置的数据采集装置 |
EP3374009B1 (en) | 2015-11-11 | 2021-01-06 | Novo Nordisk A/S | Drug delivery device with information capture |
US11103632B2 (en) | 2015-11-30 | 2021-08-31 | Sanofi-Aventis Deutschland Gmbh | Packaging assembly |
US11103633B2 (en) | 2015-11-30 | 2021-08-31 | Sanofi-Aventis Deutschland Gmbh | Packaging assembly with mounting attachment |
US10864327B2 (en) | 2016-01-29 | 2020-12-15 | Companion Medical, Inc. | Automatic medication delivery tracking |
JP7201435B6 (ja) | 2016-03-01 | 2023-01-23 | ノボ・ノルデイスク・エー/エス | 電力効率の良いアクセサリデバイス |
US20190117899A1 (en) | 2016-04-28 | 2019-04-25 | Novo Nordisk A/S | Accessory device with zero position adjustment feature |
JP6940525B2 (ja) | 2016-05-30 | 2021-09-29 | ノボ・ノルデイスク・エー/エス | ゼロ位置調節特徴を有する薬剤送達デバイス |
TWI601549B (zh) * | 2016-07-25 | 2017-10-11 | 國防醫學院 | 注射記憶筆針及其使用方法 |
CN107754058B (zh) * | 2016-08-18 | 2022-03-04 | 广东东阳光药业有限公司 | 一种注射器用数据采集方法、数据采集结构及注射器 |
JP7053598B2 (ja) * | 2016-10-14 | 2022-04-12 | エス・ハー・エル・メディカル・アクチェンゲゼルシャフト | 薬剤送達装置のためのハウジング要素、ハウジング要素に取り付けるための補助ユニット、およびハウジング要素を備える薬剤送達装置 |
JP2019532746A (ja) | 2016-10-31 | 2019-11-14 | ノボ・ノルデイスク・エー/エス | 視認機能を有する画像捕捉デバイス |
WO2018104292A1 (en) | 2016-12-05 | 2018-06-14 | Novo Nordisk A/S | Accessory device with pairing feature |
EP3570906A4 (en) | 2017-01-17 | 2020-10-21 | Kaleo, Inc. | WIRELESS CONNECTIVITY AND EVENT DETECTION DRUG DELIVERY DEVICES |
EP3884973B1 (en) | 2017-02-24 | 2022-12-07 | Sanofi | Packaging assembly for injection devices |
EP3585457B1 (en) | 2017-02-24 | 2023-11-01 | Sanofi | Packaging assembly |
US11154653B2 (en) * | 2017-05-24 | 2021-10-26 | Illinois Tool Works Inc. | Syringe barrel and syringe-confirmation assembly |
CN106983930A (zh) * | 2017-05-26 | 2017-07-28 | 南通大学附属医院 | 一种便于观察胰岛素剩余量的注射笔 |
WO2019001919A1 (en) | 2017-06-27 | 2019-01-03 | Novo Nordisk A/S | ACCESSORY DEVICE HAVING A MATCHING ELEMENT |
US11833333B2 (en) | 2017-07-12 | 2023-12-05 | Insuline Medical Ltd | Drug tracking device |
US10688247B2 (en) | 2017-07-13 | 2020-06-23 | Haselmeier Ag | Injection device with flexible dose selection |
EP3664867A4 (en) * | 2017-07-14 | 2021-06-23 | Zealand Pharma A/S | COMMUNICATION ACCESSORIES FOR AN ACTIVE INGREDIENT RELEASE DEVICE |
CN117065149A (zh) | 2017-11-23 | 2023-11-17 | 赛诺菲 | 具有旋转编码器的药剂注射装置 |
US11083852B2 (en) | 2017-12-12 | 2021-08-10 | Bigfoot Biomedical, Inc. | Insulin injection assistance systems, methods, and devices |
WO2019118537A1 (en) | 2017-12-12 | 2019-06-20 | Bigfoot Biomedical, Inc. | Therapy management systems, methods, and devices |
US10987464B2 (en) | 2017-12-12 | 2021-04-27 | Bigfoot Biomedical, Inc. | Pen cap for insulin injection pens and associated methods and systems |
US11464459B2 (en) | 2017-12-12 | 2022-10-11 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems including flash glucose monitor |
US11116899B2 (en) | 2017-12-12 | 2021-09-14 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems and devices |
US11077243B2 (en) | 2017-12-12 | 2021-08-03 | Bigfoot Biomedical, Inc. | Devices, systems, and methods for estimating active medication from injections |
CN111511427B (zh) * | 2017-12-28 | 2023-01-06 | 赛诺菲 | 用于附接到注射装置的传感器装置 |
JP2021515641A (ja) | 2018-03-09 | 2021-06-24 | ノボ・ノルデイスク・エー/エス | ログ特徴を備えた医療装置用の送信プロトコル |
JP2021519979A (ja) | 2018-04-03 | 2021-08-12 | ノボ・ノルデイスク・エー/エス | 安全なデータ送信機能 |
WO2020018433A1 (en) | 2018-07-16 | 2020-01-23 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and compliance detection |
US11969583B2 (en) | 2018-07-17 | 2024-04-30 | Medmix Switzerland Ag | Injection device with dose interruption fail safe |
KR102514837B1 (ko) * | 2018-08-30 | 2023-03-28 | 주식회사 아모라이프사이언스 | 약물주사 펜매니저 |
US11948671B2 (en) | 2019-04-11 | 2024-04-02 | Medtronic Minimed, Inc. | Intelligent accessories for medicine dispensing device |
WO2021170641A1 (en) | 2020-02-25 | 2021-09-02 | Novo Nordisk A/S | Add-on dose logging device with dose guidance functionality |
EP4251243A1 (en) | 2020-11-24 | 2023-10-04 | Novo Nordisk A/S | Fast data transmission feature for medical logging device |
KR102677092B1 (ko) * | 2022-01-12 | 2024-06-21 | 주식회사 푸른소나무 | 약물 주입 시스템 |
KR102677093B1 (ko) * | 2022-01-25 | 2024-06-21 | 주식회사 푸른소나무 | 약물 주입 시스템 |
WO2023208791A1 (en) | 2022-04-25 | 2023-11-02 | Novo Nordisk A/S | Dose logging device with scale drum scanner |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070228306A1 (en) * | 2006-03-31 | 2007-10-04 | Hand Held Products, Inc. | Optical reading device with light blocking gasket |
JP2009530002A (ja) * | 2006-03-20 | 2009-08-27 | ノボ・ノルデイスク・エー/エス | 機械的薬剤投与デバイス用の電子モジュール |
WO2010003569A1 (en) * | 2008-07-09 | 2010-01-14 | Sanofi-Aventis Deutschland Gmbh | Medication delivery device and method of assembling a medication delivery device |
US20100286612A1 (en) * | 2009-05-06 | 2010-11-11 | William Cirillo | Medication injection supervisor device |
WO2011008624A2 (en) * | 2009-07-13 | 2011-01-20 | Nestec S.A. | Cassettes and methods of using same |
WO2011117212A1 (en) * | 2010-03-22 | 2011-09-29 | Sanofi-Aventis Deutschland Gmbh | Device and method for determining information related to a medical device |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3541351A1 (de) | 1985-11-22 | 1987-06-11 | Guetermann & Co | Optische sende- und empfangsvorrichtung zum beruehrungsfreien lesen von zeichen |
US5469294A (en) * | 1992-05-01 | 1995-11-21 | Xrl, Inc. | Illumination system for OCR of indicia on a substrate |
DE29904864U1 (de) * | 1999-03-17 | 2000-08-03 | Braun Melsungen Ag | Injektionsvorrichtung mit einem Pen |
US6585698B1 (en) * | 1999-11-01 | 2003-07-01 | Becton, Dickinson & Company | Electronic medical delivery pen having a multifunction actuator |
US6547763B2 (en) * | 2000-05-18 | 2003-04-15 | Novo Nordisk A/S | Dose display for injection device |
JP4283545B2 (ja) * | 2001-05-16 | 2009-06-24 | イーライ リリー アンド カンパニー | リセット簡易化式駆動アセンブリー付きの薬物注射装置 |
PT1455878E (pt) * | 2001-12-06 | 2006-07-31 | Cardinal Health 303 Inc | Sistema de perfusao de farmacos monitorizado por co2 |
US20080269688A1 (en) * | 2005-12-08 | 2008-10-30 | Jose Colucci | Dose Indicating Assembly of a Pharmaceutical Injection Device |
CN101400393B (zh) * | 2006-03-10 | 2011-09-14 | 诺沃-诺迪斯克有限公司 | 注射装置以及在此种装置中更换药筒的方法 |
ATE520435T1 (de) | 2007-08-17 | 2011-09-15 | Novo Nordisk As | Medizinische vorrichtung mit wertesensor |
JPWO2010070799A1 (ja) * | 2008-12-16 | 2012-05-24 | パナソニック株式会社 | 薬剤投与装置 |
TWI428160B (zh) * | 2009-04-01 | 2014-03-01 | Shl Group Ab | 藥物輸送裝置 |
KR101721906B1 (ko) * | 2009-04-29 | 2017-03-31 | 애브비 바이오테크놀로지 리미티드 | 자동 주입 장치 |
JP6175049B2 (ja) * | 2011-03-30 | 2017-08-02 | ノボ・ノルデイスク・エー/エス | 患者の長期薬剤投与計画の最適化システム |
ES2691492T3 (es) * | 2011-09-22 | 2018-11-27 | Abbvie Inc. | Porta-jeringa para un dispositivo automático de inyección |
US20140378801A1 (en) * | 2011-09-27 | 2014-12-25 | Novo Nordisk A/S | Medical System Configured to Collect and Transfer Data |
WO2013144020A1 (de) * | 2012-03-30 | 2013-10-03 | Tecpharma Licensing Ag | Injektionsvorrichtung mit einem relativ zu einem gehäuse verschiebbaren dosisanzeigeelement |
-
2013
- 2013-02-08 KR KR1020147024608A patent/KR20140124813A/ko not_active Application Discontinuation
- 2013-02-08 TW TW102105073A patent/TWI581814B/zh not_active IP Right Cessation
- 2013-02-08 EP EP13704404.6A patent/EP2814544B1/en active Active
- 2013-02-08 BR BR112014019511A patent/BR112014019511A8/pt not_active IP Right Cessation
- 2013-02-08 US US14/373,136 patent/US9233210B2/en active Active
- 2013-02-08 DK DK13704404.6T patent/DK2814544T3/en active
- 2013-02-08 RU RU2014137154A patent/RU2628052C2/ru not_active IP Right Cessation
- 2013-02-08 JP JP2014556065A patent/JP6203198B2/ja active Active
- 2013-02-08 CN CN201380019692.8A patent/CN104363940B/zh active Active
- 2013-02-08 AU AU2013220538A patent/AU2013220538B2/en not_active Ceased
- 2013-02-08 WO PCT/EP2013/052508 patent/WO2013120776A1/en active Application Filing
- 2013-02-08 MX MX2014009764A patent/MX350049B/es active IP Right Grant
-
2014
- 2014-07-03 IL IL233508A patent/IL233508A0/en unknown
- 2014-12-31 HK HK14113146.0A patent/HK1199623A1/zh unknown
-
2015
- 2015-12-07 US US14/961,204 patent/US20160101234A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009530002A (ja) * | 2006-03-20 | 2009-08-27 | ノボ・ノルデイスク・エー/エス | 機械的薬剤投与デバイス用の電子モジュール |
US20070228306A1 (en) * | 2006-03-31 | 2007-10-04 | Hand Held Products, Inc. | Optical reading device with light blocking gasket |
WO2010003569A1 (en) * | 2008-07-09 | 2010-01-14 | Sanofi-Aventis Deutschland Gmbh | Medication delivery device and method of assembling a medication delivery device |
US20100286612A1 (en) * | 2009-05-06 | 2010-11-11 | William Cirillo | Medication injection supervisor device |
WO2010128493A2 (en) * | 2009-05-06 | 2010-11-11 | John Hughes | Medication injection supervisor device |
WO2011008624A2 (en) * | 2009-07-13 | 2011-01-20 | Nestec S.A. | Cassettes and methods of using same |
WO2011117212A1 (en) * | 2010-03-22 | 2011-09-29 | Sanofi-Aventis Deutschland Gmbh | Device and method for determining information related to a medical device |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019501697A (ja) * | 2015-12-10 | 2019-01-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 薬物送達デバイスに着脱可能に取り付け可能なセンサデバイス |
JP2021178215A (ja) * | 2015-12-10 | 2021-11-18 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 薬物送達デバイスに着脱可能に取り付け可能なセンサデバイス |
US11241542B2 (en) | 2015-12-10 | 2022-02-08 | Sanofi-Aventis Deutschland Gmbh | Sensor device removably attachable to a drug delivery device |
JP7191168B2 (ja) | 2015-12-10 | 2022-12-16 | サノフィ-アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 薬物送達デバイスに着脱可能に取り付け可能なセンサデバイス |
JP2019520880A (ja) * | 2016-05-30 | 2019-07-25 | ノボ・ノルデイスク・エー/エス | アクセサリデバイスのための取付け特徴 |
US11395882B2 (en) | 2016-08-26 | 2022-07-26 | Sanofi-Aventis Deutschland Gmbh | Device for attachment to an injection device |
Also Published As
Publication number | Publication date |
---|---|
RU2628052C2 (ru) | 2017-08-14 |
KR20140124813A (ko) | 2014-10-27 |
US20160101234A1 (en) | 2016-04-14 |
EP2814544B1 (en) | 2016-07-06 |
CN104363940A (zh) | 2015-02-18 |
BR112014019511A2 (ja) | 2017-06-20 |
MX2014009764A (es) | 2014-09-12 |
US9233210B2 (en) | 2016-01-12 |
CN104363940B (zh) | 2016-12-07 |
MX350049B (es) | 2017-08-24 |
TW201345579A (zh) | 2013-11-16 |
IL233508A0 (en) | 2014-08-31 |
EP2814544A1 (en) | 2014-12-24 |
WO2013120776A1 (en) | 2013-08-22 |
DK2814544T3 (en) | 2016-10-24 |
RU2014137154A (ru) | 2016-04-10 |
TWI581814B (zh) | 2017-05-11 |
US20140354998A1 (en) | 2014-12-04 |
HK1199623A1 (zh) | 2015-07-10 |
BR112014019511A8 (pt) | 2017-07-11 |
AU2013220538A1 (en) | 2014-08-21 |
JP6203198B2 (ja) | 2017-09-27 |
AU2013220538B2 (en) | 2017-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6203198B2 (ja) | 注射デバイスへの取付けのための補助デバイス | |
JP6340321B2 (ja) | ペン型注射デバイス、およびペン型注射デバイスのための電子クリップ式モジュール | |
JP6554145B2 (ja) | ペン型注射デバイスおよびそのための電子クリップオン・モジュール | |
JP6687665B2 (ja) | 用量設定および投与を監視およびログ記録するペン型薬物注射デバイスおよび電子増設監視モジュール | |
US20220096005A1 (en) | Supplementary Device for a Manually Operable Injection Device | |
JP6261579B2 (ja) | 用量設定および投与を監視およびログ記録するペン型薬物注射デバイスおよび電子増設監視モジュール | |
JP6385927B2 (ja) | 注射デバイスに取り付けるための補足デバイス | |
CN107257697B (zh) | 具有辅助装置的注射装置 | |
CN110494180B (zh) | 用于附接到注射装置的监测装置 | |
JP7260568B2 (ja) | ペン型注射デバイス、およびペン型注射デバイスのための電子クリップ式モジュール | |
JP6869388B2 (ja) | ペン型注射デバイスおよびそのための電子クリップオン・モジュール |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160126 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160126 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161028 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170207 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170801 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170829 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6203198 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |